vs
Side-by-side financial comparison of Granite Ridge Resources, Inc. (GRNT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $128.3M, roughly 1.4× Granite Ridge Resources, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -36.7%, a 38.3% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 4.3%). Over the past eight quarters, Granite Ridge Resources, Inc.'s revenue compounded faster (18.9% CAGR vs -0.2%).
Granite Ridge Resources, Inc. is an independent upstream energy company focused on the exploration, development, and production of oil, natural gas, and natural gas liquids. It operates low-cost, high-yield onshore hydrocarbon assets across key U.S. basins, primarily serving North American energy markets.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GRNT vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $128.3M | $177.4M |
| Net Profit | $-47.0M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | -36.7% | 1.6% |
| Revenue YoY | 4.3% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.36 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $128.3M | $177.4M | ||
| Q4 25 | $105.5M | $196.9M | ||
| Q3 25 | $112.7M | $179.5M | ||
| Q2 25 | $109.2M | $181.1M | ||
| Q1 25 | $122.9M | $168.9M | ||
| Q4 24 | $106.3M | $187.3M | ||
| Q3 24 | $94.1M | $168.6M | ||
| Q2 24 | $90.7M | $178.0M |
| Q1 26 | $-47.0M | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $14.5M | $5.4M | ||
| Q2 25 | $25.1M | $-4.8M | ||
| Q1 25 | $9.8M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.1M | $-143.5M | ||
| Q2 24 | $5.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -34.5% | 1.2% | ||
| Q3 25 | 17.4% | 3.5% | ||
| Q2 25 | 19.0% | 4.7% | ||
| Q1 25 | 34.6% | 1.2% | ||
| Q4 24 | -6.5% | 13.2% | ||
| Q3 24 | 26.2% | -82.8% | ||
| Q2 24 | 24.1% | 15.9% |
| Q1 26 | -36.7% | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 12.9% | 3.0% | ||
| Q2 25 | 23.0% | -2.7% | ||
| Q1 25 | 8.0% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 9.6% | -85.1% | ||
| Q2 24 | 5.6% | 10.6% |
| Q1 26 | $-0.36 | $0.07 | ||
| Q4 25 | $-0.19 | $0.05 | ||
| Q3 25 | $0.11 | $0.12 | ||
| Q2 25 | $0.19 | $-0.11 | ||
| Q1 25 | $0.07 | $0.10 | ||
| Q4 24 | $-0.09 | $0.38 | ||
| Q3 24 | $0.07 | $-3.11 | ||
| Q2 24 | $0.04 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | $26.3M | — |
| Stockholders' EquityBook value | $545.6M | $653.9M |
| Total Assets | $1.2B | $1.2B |
| Debt / EquityLower = less leverage | 0.05× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | $26.3M | — | ||
| Q4 25 | $367.8M | $372.2M | ||
| Q3 25 | $300.0M | $376.7M | ||
| Q2 25 | $275.0M | $580.5M | ||
| Q1 25 | $250.0M | $583.4M | ||
| Q4 24 | $205.0M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $545.6M | $653.9M | ||
| Q4 25 | $605.8M | $693.1M | ||
| Q3 25 | $643.9M | $727.2M | ||
| Q2 25 | $642.5M | $757.8M | ||
| Q1 25 | $631.4M | $798.5M | ||
| Q4 24 | $635.4M | $778.3M | ||
| Q3 24 | $660.6M | $749.6M | ||
| Q2 24 | $665.3M | $879.3M |
| Q1 26 | $1.2B | $1.2B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $990.5M | $1.6B |
| Q1 26 | 0.05× | — | ||
| Q4 25 | 0.61× | 0.54× | ||
| Q3 25 | 0.47× | 0.52× | ||
| Q2 25 | 0.43× | 0.77× | ||
| Q1 25 | 0.40× | 0.73× | ||
| Q4 24 | 0.32× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $58.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 47.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $58.3M | — | ||
| Q4 25 | $64.5M | $43.7M | ||
| Q3 25 | $77.8M | $60.8M | ||
| Q2 25 | $78.0M | $12.0M | ||
| Q1 25 | $76.1M | $35.5M | ||
| Q4 24 | $68.2M | $33.1M | ||
| Q3 24 | $74.7M | $53.9M | ||
| Q2 24 | $64.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | 47.1% | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 5.36× | 11.20× | ||
| Q2 25 | 3.11× | — | ||
| Q1 25 | 7.75× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.25× | — | ||
| Q2 24 | 12.58× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GRNT
| Oil sales | $103.4M | 81% |
| Natural gas and related product sales | $24.8M | 19% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
